Iambic Therapeutics (IAM) prices IPO at $16, raising $150 million on Nasdaq
As seen on the 24/7 Wall St. homepage on October 15, 2026.
Iambic Therapeutics prices IPO at $16, raising $150 million
Priced at $16 a share, the AI drug discovery developer raised $150 million on 9.375 million shares, with J.P. Morgan, Jefferies, BofA and Citigroup running the books. Terms are final, so trading opens from here.
Continue ReadingShow less
Iambic Therapeutics, an AI-driven drug discovery company, priced its IPO at $16 per share, and shares begin trading on Nasdaq now that terms are final.
J.P. Morgan, Jefferies, BofA, and Citigroup served as joint bookrunners, a syndicate lineup that reflects institutional-grade demand and broad distribution reach. That underwriting muscle typically signals meaningful buy-side interest heading into the first day of trading.
The $150 million raised gives Iambic a sizable war chest to advance its AI-powered approach to drug discovery, a field drawing heavy investor attention as machine-learning tools accelerate early-stage pharmaceutical research. How the company deploys that capital is the key signal for investors tracking AI in biotech.
Investors wanting the company's structure, use of proceeds, and risk disclosures should go directly to the prospectus on file with the SEC before making any trading decisions.
Mentioned: IAM